Alexa

Breast cancer drug

Breast cancer drug

Swiss drugmaker Roche Holding AG said a new study showed women with early-stage HER2 positive breast cancer continue to benefit from its Herceptin drug several years after treatment is completed.
The patients were treated for one year with Herceptin and then monitored for four years. They enjoyed a longer, disease-free life as a result of the treatment, the drugmaker said.
Roche, the world's largest maker of cancer drugs, said the study also confirmed the long-term safety profile of Herceptin.


Updated : 2021-03-01 00:39 GMT+08:00